The Amzeeq (minocycline; Foamix) topical foam 4% has received FDA approval for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients older than nine years.
Minocycline is a tetracycline-class drug, which has effectively been used in acne treatment for decades, but was hitherto available only as oral or systemic formulations. It will be available as a foam in a 30-gram aerosol container, from January 2020. It’s the first FDA-approved topical minocycline treatment for acne vulgaris.
Amzeeq was well-tolerated during trials; improvements were noticed with no serious adverse effects other than headaches.
Read the article click here